GLP-1 agonists

Background

  • Synthetic glucagon-like peptide-1 (GLP-1) receptor agonists
  • Released by L-cells of the small intestine in response to the presence of nutrients
  • Stimulate insulin release from pancreatic islet cells. It does this by stimulating glucose-dependent insulin release in the islet cells of the pancreas
  • Slows gastric emptying times
  • Increases satiety, which decreases drive for food intake

GLP-1 Agonist Types

Short Acting Dose
Exenatide (Byetta) 5-10 mcg SC bid
Liraglutide (Victoza, Saxenda) 0.6-1.8 mg SC daily
Long Acting
Exenatide (Bydureon) 2 mg SC qwk
Albiglutide (Tanzeum) 30-50 mg SC qwk
Dulaglutide (Trulicity) 0.75-1.5 mg qwk
  • Lixisenatide (Lyxumia, Adlyxin)
  • Semaglutide (Ozempic, Rybelsus, Wegovy)
  • Tirzepatide^ (Mounjaro, Zepbound)

^Dual GLP-1 and GIP agonist

Indication

Adverse Reactions

  • Nausea, vomiting, diarrhea
  • Acute pancreatitis
  • Exenatide should not be used in patients with creatinine clearance below 30mL/min
  • Should not be used if personal of family history of medullary thyroid cancer or MEN 2A/2B

See Also

References

  1. Epocrates
  2. http://www.uptodate.com/contents/glucagon-like-peptide-1-receptor-agonists-for-the-treatment-of-type-2-diabetes-mellitus?source=see_link&sectionName=GLUCAGON-LIKE+PEPTIDE-1&anchor=H2#H619400